ReviewInternational journal of molecular sciences2021
Anti-PD1/PD-L1 Immunotherapy for Non-Small Cell Lung Cancer with Actionable Oncogenic Driver Mutations.
Review in International journal of molecular sciences, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 97 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
97 citing papers in PubMed, 2 syntheses or guidelines pooled it, 132 citations in OpenAlex.
- Diagnostic accuracy of ¹⁸F-FDG PET/CT radiomics for non-invasive prediction of PD-L1 expression in non-small cell lung cancer: A systematic review and meta-analysis.Annals of nuclear medicine · 2026Pooled it
- Research trends in lung cancer and the tumor microenvironment: a bibliometric analysis of studies published from 2014 to 2023.Frontiers in oncology · 2024Pooled it
- Recent advances in engineered nanozymes for precision lung cancer therapy.Materials today. Bio · 2026Review
- Review
- Synergistic Effect of Linebacker-1 With Radiation Therapy in a Mouse Lung Cancer Model.Advances in radiation oncology · 2026Article
- CBFA2T3 as a Key Prognostic Biomarker in Lung Adenocarcinoma: Insights from Comprehensive Analysis and Validation.Biochemical genetics · 2026Article
- Methylated circulating tumor DNA: technical challenges and clinical applications in non-small cell lung cancer patients-a narrative review.Translational lung cancer research · 2026Review
- Tumor-intrinsic PD-L1 drives lung cancer progression in response to TLR stimulation by promoting autophagy through the TRAF6-BECN1 signaling axis.Experimental hematology & oncology · 2026Article
- Enhancing Immunotherapy in Lung Cancer: The Promise of dMMR/MSI-H Tumors and Immune Checkpoint Inhibitors.Health science reports · 2026Article
- Review
- Eosinophils in lung cancer: from inflammatory cytokines to immunotherapeutic biomarkers.Frontiers in immunology · 2026Review
- Spontaneous cSCC Murine Model Shows Limited Response to PD-1 Blockade and Radiation Combination Therapy.Cancers · 2025Article
- The role of nursing in enhancing quality of life for lung cancer patients receiving targeted and immunotherapy: Challenges, opportunities, and future directions.Human vaccines & immunotherapeutics · 2025Review
- T cell exhaustion‑related gene CD79B predicts prognosis, inhibits malignant progression and promotes tumor‑associated macrophage M1‑like polarization in lung adenocarcinoma.Oncology reports · 2025Article
- Observational
- Molecular and clonal evolution of primary lesionsTranslational lung cancer research · 2025Article
- Association of Erythrocyte-Related Indices with Immune-Related Adverse Events and Survival of Lung Cancer Patients Receiving Immune Checkpoint Inhibitors.Pharmaceuticals (Basel, Switzerland) · 2025Article
- [Advances in Targeted Therapy for Advanced Non-small Cell Lung Cancer with HER2 Mutation].Zhongguo fei ai za zhi = Chinese journal of lung cancer · 2025Review
- Adjuvant Immunotherapy in Stage IIB/IIC Melanoma: Current Evidence and Future Directions.Biomedicines · 2025Review
- MET Exon 14 Skipping Mutations in Lung Cancer: Clinical-Pathological Characteristics and Immune Microenvironment.Current oncology (Toronto, Ont.) · 2025Article
37 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Anti-PD1/PD-L1 immunotherapy has emerged as a standard of care for stage III-IV non-small cell lung cancer (NSCLC) over the past decade. Patient selection is usually based on PD-L1 expression by tumor cells and/or tumor mutational burden. However, mutations in oncogenic drivers such as
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.